Internalization of ACE2 and hypofibrinolysis can lead to reduced degradation of bradykinin (KER2352), raising bradykinin levels and activities (KE 1867, Bradykinin system, hyperactivated), which could explain many of the symptoms associated with COVID-19, including vasodilation, hypotension, vascular permeability and hyperinflammation (KER2357). This evidence concerns the gene ACE2 and COVID-19.